NASDAQ:VNDA Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis $4.75 +0.24 (+5.32%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$4.65 -0.10 (-2.02%) As of 08/22/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Vanda Pharmaceuticals Stock (NASDAQ:VNDA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vanda Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.52▼$4.7850-Day Range$4.19▼$5.0252-Week Range$3.81▼$5.55Volume340,378 shsAverage Volume554,926 shsMarket Capitalization$280.67 millionP/E RatioN/ADividend YieldN/APrice Target$16.50Consensus RatingStrong Buy Company Overview Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia. Read More Vanda Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreVNDA MarketRank™: Vanda Pharmaceuticals scored higher than 88% of companies evaluated by MarketBeat, and ranked 134th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingVanda Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageVanda Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Vanda Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vanda Pharmaceuticals are expected to grow in the coming year, from ($1.12) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vanda Pharmaceuticals is -4.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vanda Pharmaceuticals is -4.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVanda Pharmaceuticals has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Vanda Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.23% of the float of Vanda Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVanda Pharmaceuticals has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Vanda Pharmaceuticals has recently decreased by 1.31%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVanda Pharmaceuticals does not currently pay a dividend.Dividend GrowthVanda Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.77 Percentage of Shares Shorted8.23% of the float of Vanda Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVanda Pharmaceuticals has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Vanda Pharmaceuticals has recently decreased by 1.31%, indicating that investor sentiment is improving. News and Social Media1.7 / 5News Sentiment0.12 News SentimentVanda Pharmaceuticals has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Vanda Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for VNDA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vanda Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,130.00 in company stock.Percentage Held by InsidersOnly 10.00% of the stock of Vanda Pharmaceuticals is held by insiders.Percentage Held by Institutions88.14% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vanda Pharmaceuticals' insider trading history. Receive VNDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address VNDA Stock News HeadlinesVanda seeks FDA Commissioner review of Hetlioz generic rulingAugust 22 at 7:57 AM | msn.comVanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®August 21 at 4:40 PM | prnewswire.comGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free. | Stansberry Research (Ad)Vanda Pharmaceuticals shares rise after court overturns FDA denialAugust 18, 2025 | za.investing.comVanda Pharmaceuticals Shares Climb After Court Reverses FDA DecisionAugust 18, 2025 | msn.comVanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-MarkAugust 18, 2025 | msn.comIn a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag DisorderAugust 18, 2025 | prnewswire.comHC Wainwright Has Pessimistic Outlook of VNDA Q3 EarningsAugust 15, 2025 | americanbankingnews.comSee More Headlines VNDA Stock Analysis - Frequently Asked Questions How have VNDA shares performed this year? Vanda Pharmaceuticals' stock was trading at $4.79 at the start of the year. Since then, VNDA shares have decreased by 0.8% and is now trading at $4.75. How were Vanda Pharmaceuticals' earnings last quarter? Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) posted its quarterly earnings data on Thursday, July, 31st. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.12. The biopharmaceutical company had revenue of $52.59 million for the quarter, compared to analysts' expectations of $54.77 million. Vanda Pharmaceuticals had a negative trailing twelve-month return on equity of 12.89% and a negative net margin of 32.90%. Read the conference call transcript. Who are Vanda Pharmaceuticals' major shareholders? Vanda Pharmaceuticals' top institutional shareholders include Acadian Asset Management LLC (2.93%), Geode Capital Management LLC (2.86%), Krensavage Asset Management LLC (1.73%) and Connor Clark & Lunn Investment Management Ltd. (1.47%). Insiders that own company stock include Mihael Hristos Polymeropoulos, Kevin Patrick Moran, Joakim Wijkstrom, Stephen Ray Mitchell and Timothy Williams. View institutional ownership trends. How do I buy shares of Vanda Pharmaceuticals? Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vanda Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vanda Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), GE Aerospace (GE), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings7/31/2025Today8/24/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:VNDA CIK1347178 Webwww.vandapharma.com Phone(202) 734-3400Fax202-296-1450Employees290Year Founded2002Price Target and Rating Average Price Target for Vanda Pharmaceuticals$16.50 High Price Target$20.00 Low Price Target$13.00 Potential Upside/Downside+247.4%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.90 million Net Margins-32.90% Pretax Margin-41.77% Return on Equity-12.89% Return on Assets-10.47% Debt Debt-to-Equity RatioN/A Current Ratio3.25 Quick Ratio3.23 Sales & Book Value Annual Sales$203.47 million Price / Sales1.38 Cash FlowN/A Price / Cash FlowN/A Book Value$8.23 per share Price / Book0.58Miscellaneous Outstanding Shares59,089,000Free Float53,180,000Market Cap$280.67 million OptionableOptionable Beta0.72 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:VNDA) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.